Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Apis Flagship Fund delivered strong performance in the fourth quarter of 2025, with the Fund up 10.0% net for the quarter and gaining 55.1% for the full year, significantly outperforming the MSCI ACWI global benchmark by approximately 7.0% in Q4 and 33.0% for the year. Long positions drove the majority of gains as they generated 11.9% gross contribution, while shorts added a further 0.8% gross, with the portfolio positioned around 68% net long as of December. Performance was broad-based, as Technology and Healthcare led quarterly returns, and strong contributions also came from basic materials, while small-capitalization stocks narrowed their traditional underperformance relative to large caps. Looking ahead, the firm highlighted its continued emphasis on bottom-up stock selection, structural exposures to niche opportunities across healthcare, semiconductors, and industrials, and the persistent attractiveness of non-U.S. markets as key drivers for future potential returns. In addition, please check the Fund’s top five holdings to know its best picks in 2025.
In its fourth-quarter 2025 investor letter, Apis Capital Advisors highlighted stocks like uniQure (NASDAQ:QURE).uniQure (NASDAQ:QURE) is a gene therapy company focused on developing one-time treatments for rare and neurological diseases using its proprietary AAV-based delivery technology. The one-month return of uniQure (NASDAQ:QURE) was 0.44% while its shares traded between $7.76 and $71.50 over the last 52 weeks. On January 30, 2026, uniQure (NASDAQ:QURE) stock closed at approximately $22.72 per share, with a market capitalization of about $1.4 billion.
Apis Capital Advisors’ Apis Flagship Fund stated the following regarding uniQure (NASDAQ:QURE) in its Q4 2025 investor letter:
“uniQure (NASDAQ:QURE) detracted about 1.1%, while several of our Korean defense-related holdings collectively detracted approximately 2.5% in Q4. We attribute this weakness to a technical pause following strong prior performance rather than any deterioration in fundamentals.”
LightField Studios/Shutterstock.com
uniQure (NASDAQ:QURE) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 59 hedge fund portfolios held uniQure (NASDAQ:QURE) at the end of the third quarter, which was 36 in the previous quarter. While we acknowledge the risk and potential of uniQure (NASDAQ:QURE) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
